Skip to main content
. 2020 Aug 3;6(10):FSO608. doi: 10.2144/fsoa-2020-0070

Figure 2. . Immunotherapy treatment.

Figure 2. 

Most patients received either pembrolizumab or nivolumab, but there were 24 patients who received ipilimumab and three patients who received combination ipilimumab plus nivolumab. A small number of patients were treated with the PD-L1 inhibitors atezolizumab or durvalumab.